Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 184

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 184
---
 AND CASH EQUIVALENTS AT THE END OF PERIOD                              |     |                |  3,268 |   |     |                |    729 |   |     |                    |  1,186 |   |

<div align='center'>The accompanying notes are an integral part of
these financial statements.

F-7</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 1:– GENERAL

On December
17, 2024, the Company completed the redomicile from the State of Delaware to the State of Nevada (the “Reincorporation. As a result
of the Reincorporation, the Company ceased its business existence as a Delaware corporation and continued its business existence as a
Nevada corporation under the name “Revium Rx.”

In November
2023, the Successor entered into a stock exchange agreement (“Share Exchange”) with Lipovation Ltd, a private Israeli company
engaged in the development of novel pharmaceutical solutions (“Lipovation” or the “Predecessor”). Following the closing
of such agreement on July 23, 2024, the Predecessor became a new wholly owned subsidiary of the Company, and as determined by the Company’s
board of directors. Following the closing of the Share Exchange agreement, the Company’s Board of Directors determined to discontinue
all of the Company’s prior activities and efforts in the development and activation of the clinical decision-making support system
which constituted the business of the Successor prior to the closing of the stock exchange agreement, and to focus on the development
of the acquired LipoVation’s business, refer to Note 3.

| b. | Liquidityand management plans: |

The Company
is in the research and development (R&D) stage and, as such, has not generated any revenues from its current operations. The Company’s
activities are primarily funded through investment. As of December 31, 2024, the Company reported an accumulated deficit of $11,513.

To support
its operations and advance its development programs, the Company intends to continue securing investments. Management anticipates that
additional capital will be necessary to fund its ongoing R&D activities and to explore opportunities for acquiring healthcare or healthcare-related
technologies. However, there are currently no binding commitments for further investment, and there can be no assurance that the Company
will secure the required capital on commercially reasonable terms, or at